RTP-100

RTP-100 is a preclinical-stage peptide therapeutic being developed by ResoTher Pharma, a Danish biotechnology company. It is part of the company's broader pipeline of synthetic peptide-based therapeutics designed to target inflammatory resolution pathways. While ResoTher Pharma's lead candidate, RTP-026, is a well-characterized Annexin A1 mimetic targeting the formyl peptide receptor type 2 (FPR2), the specific biological target, mechanism of action, and primary therapeutic indications for the RTP-100 series have not yet been publicly disclosed. The program is currently focused on acute and critical care cardiovascular indications, consistent with the company's specialization in cardiovascular disease and inflammatory resolution.